Expect Buzz About Rebyota Fecal Product for C. diff

March 2023

New Rx Rebyota will be the first FDA-approved “fecal microbiota” product for preventing C. difficile recurrence in adults.

A fecal transplant may seem unappealing...but it can help restore healthy flora, or microbiota, in the gastrointestinal (GI) tract.

And C. diff infections are a big deal. They can cause severe diarrhea and life-threatening colon inflammation. Plus they’re becoming more difficult to treat.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Anticipate That RFID Will Become More Common
Anesthesia Help Treat Malignant Hyperthermia Within 10 Minutes
Anticonvulsants Use Strategies to Ensure Safety With Antiseizure Meds
Infectious Diseases Expect Buzz About Rebyota Fecal Product for C. diff
Dermatology Prevent Mishaps With Meds for Psoriasis
COPD Be Ready to Dispense More Combo Inhalers for COPD
Med Administration Stay Alert for Issues With Meds Given Via Tube
Hypotension Minimize Issues With Meds for Orthostatic Hypotension
Poison Prevention Provide Strategies to Prevent Poisonings

Expect Buzz About Rebyota Fecal Product for C. diff

Practical advice for a better career, with unlimited access to CE

Table of Contents